236 related articles for article (PubMed ID: 14745721)
1. Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patients.
Ghiorzo P; Villaggio B; Sementa AR; Hansson J; Platz A; Nicoló G; Spina B; Canepa M; Palmer JM; Hayward NK; Bianchi-Scarrà G
Hum Pathol; 2004 Jan; 35(1):25-33. PubMed ID: 14745721
[TBL] [Abstract][Full Text] [Related]
2. p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry.
Sparrow LE; Eldon MJ; English DR; Heenan PJ
Am J Dermatopathol; 1998 Jun; 20(3):255-61. PubMed ID: 9650698
[TBL] [Abstract][Full Text] [Related]
3. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.
Goel VK; Ibrahim N; Jiang G; Singhal M; Fee S; Flotte T; Westmoreland S; Haluska FS; Hinds PW; Haluska FG
Oncogene; 2009 Jun; 28(23):2289-98. PubMed ID: 19398955
[TBL] [Abstract][Full Text] [Related]
4. Genome-Wide Overexpression Screen Identifies Genes Able to Bypass p16-Mediated Senescence in Melanoma.
Lee WJ; Škalamera D; Dahmer-Heath M; Shakhbazov K; Ranall MV; Fox C; Lambie D; Stevenson AJ; Yaswen P; Gonda TJ; Gabrielli B
SLAS Discov; 2017 Mar; 22(3):298-308. PubMed ID: 27872202
[TBL] [Abstract][Full Text] [Related]
5. Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions.
Keller-Melchior R; Schmidt R; Piepkorn M
J Invest Dermatol; 1998 Jun; 110(6):932-8. PubMed ID: 9620301
[TBL] [Abstract][Full Text] [Related]
6. Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma.
Ghiorzo P; Gargiulo S; Pastorino L; Nasti S; Cusano R; Bruno W; Gliori S; Sertoli MR; Burroni A; Savarino V; Gensini F; Sestini R; Queirolo P; Goldstein AM; Scarrà GB
Hum Mol Genet; 2006 Sep; 15(18):2682-9. PubMed ID: 16893909
[TBL] [Abstract][Full Text] [Related]
7. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.
Reed JA; Loganzo F; Shea CR; Walker GJ; Flores JF; Glendening JM; Bogdany JK; Shiel MJ; Haluska FG; Fountain JW
Cancer Res; 1995 Jul; 55(13):2713-8. PubMed ID: 7796391
[TBL] [Abstract][Full Text] [Related]
8. Familial cutaneous melanoma.
Hansson J
Adv Exp Med Biol; 2010; 685():134-45. PubMed ID: 20687502
[TBL] [Abstract][Full Text] [Related]
9. CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma.
McNeal AS; Liu K; Nakhate V; Natale CA; Duperret EK; Capell BC; Dentchev T; Berger SL; Herlyn M; Seykora JT; Ridky TW
Cancer Discov; 2015 Oct; 5(10):1072-85. PubMed ID: 26183406
[TBL] [Abstract][Full Text] [Related]
10. Reduced p16 and increased cyclin D1 and pRb expression are correlated with progression in cutaneous melanocytic tumors.
Karim RZ; Li W; Sanki A; Colman MH; Yang YH; Thompson JF; Scolyer RA
Int J Surg Pathol; 2009 Oct; 17(5):361-7. PubMed ID: 19666944
[TBL] [Abstract][Full Text] [Related]
11. An analysis of p16 protein expression in sporadic malignant melanoma.
Grover R; Chana JS; Wilson GD; Richman PI; Sanders R
Melanoma Res; 1998 Jun; 8(3):267-72. PubMed ID: 9664149
[TBL] [Abstract][Full Text] [Related]
12. Loss of p16 expression and copy number changes of CDKN2A in a spectrum of spitzoid melanocytic lesions.
Harms PW; Hocker TL; Zhao L; Chan MP; Andea AA; Wang M; Harms KL; Wang ML; Carskadon S; Palanisamy N; Fullen DR
Hum Pathol; 2016 Dec; 58():152-160. PubMed ID: 27569296
[TBL] [Abstract][Full Text] [Related]
13. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry of p16 in nevi of pregnancy and nevoid melanomas.
Koh SS; Roehmholdt BF; Cassarino DS
J Cutan Pathol; 2018 Dec; 45(12):891-896. PubMed ID: 30178478
[TBL] [Abstract][Full Text] [Related]
15. A melanoma-predisposing germline CDKN2A mutation with functional significance for both p16 and p14ARF.
Hashemi J; Lindström MS; Asker C; Platz A; Hansson J; Wiman KG
Cancer Lett; 2002 Jun; 180(2):211-21. PubMed ID: 12175554
[TBL] [Abstract][Full Text] [Related]
16. p16 Range of expression in dermal predominant benign epithelioid and spindled nevi and melanoma.
Oaxaca G; Billings SD; Ko JS
J Cutan Pathol; 2020 Sep; 47(9):815-823. PubMed ID: 32330325
[TBL] [Abstract][Full Text] [Related]
17. [From gene to disease; from p16 to melanoma].
Gruis NA; Bergman W
Ned Tijdschr Geneeskd; 2000 Oct; 144(44):2100-2. PubMed ID: 11103670
[TBL] [Abstract][Full Text] [Related]
18. The Amount of Melanin Influences p16 Loss in Spitzoid Melanocytic Lesions: Correlation With CDKN2A Status by FISH and MLPA.
Martinez Ciarpaglini C; Gonzalez J; Sanchez B; Agusti J; Navarro L; Nieto G; Monteagudo C
Appl Immunohistochem Mol Morphol; 2019 Jul; 27(6):423-429. PubMed ID: 29489509
[TBL] [Abstract][Full Text] [Related]
19. CDKN2A and MC1R variants influence dermoscopic and confocal features of benign melanocytic lesions in multiple melanoma patients.
Bassoli S; Maurichi A; Rodolfo M; Casari A; Frigerio S; Pupelli G; Farnetani F; Pelosi G; Santinami M; Pellacani G
Exp Dermatol; 2013 Jun; 22(6):411-6. PubMed ID: 23711066
[TBL] [Abstract][Full Text] [Related]
20. Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms.
McBride JD; McAfee JL; Piliang M; Bergfeld WF; Fernandez AP; Ronen S; Billings SD; Ko JS
J Cutan Pathol; 2022 Mar; 49(3):220-230. PubMed ID: 34476825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
